Mallinckrodt Completes Merger with Endo to Form Global Therapeutics Leader
August 1, 2025
Mallinckrodt plc and Endo, Inc. completed their merger to create a global, scaled, diversified therapeutics leader. The transaction combines Mallinckrodt’s branded portfolio with Endo’s generics and sterile injectables business (Par Health), which is intended to be spun off as a standalone independent company targeted for the fourth quarter of 2025.
- Buyers
- Mallinckrodt plc
- Targets
- Endo, Inc.
- Industry
- Pharmaceuticals
- Location
- Ireland
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Knight Therapeutics Acquires Endo's International Pharmaceuticals Business (Paladin Pharma)
June 17, 2025
Pharmaceuticals
Knight Therapeutics has completed the acquisition of Endo's International Pharmaceuticals business, primarily operated through Canada-based Paladin Pharma Inc. The divestiture closed for up to approximately $105 million in cash (about $79 million at closing, ~$11 million in permitted holdbacks and up to $15 million contingent on milestones).
-
MedPharm and Tergus Pharma Merge to Create Topical & Transdermal CDMO Leader
July 8, 2024
Pharmaceuticals
MedPharm and Tergus Pharma have merged and will operate under the MedPharm name to create an integrated, end-to-end topical and transdermal CDMO. Ampersand Capital Partners and Bourne Partners Strategic Capital assume majority ownership of the combined company while Great Point Partners retains a significant minority stake; Michael Kane is appointed CEO and Patrick Walsh remains Executive Chairman.
-
Norstella and Citeline Merge to Create $5B Global Pharma Technology Company
June 28, 2022
Data & Analytics
Norstella (the group of Evaluate, MMIT, Panalgo and The Dedham Group) announced an agreement to merge with Citeline (formerly Pharma Intelligence) to form a combined global pharmaceutical technology and intelligence business valued at about $5 billion. The combination brings clinical trial intelligence, commercial data and real‑world analytics together to offer an end‑to‑end suite of solutions for life sciences companies; the deal involves financial sponsors including Hg (Norstella) and Warburg Pincus (Citeline).
-
ERT Merges with Bioclinica to Create Global Clinical Trial Endpoint Leader
December 10, 2020
Healthcare Services
ERT has merged with Bioclinica to create a global leader in clinical trial endpoint technology, combining Bioclinica's imaging and eClinical capabilities with ERT's expertise in eCOA, cardiac safety, respiratory and wearables. The transaction was completed in 2021 with Cinven (Bioclinica's owner) becoming a significant minority shareholder in ERT alongside Nordic Capital, Astorg and Novo Holdings A/S.
-
MEI Pharma and Infinity Pharmaceuticals Announce Definitive All-Stock Merger
February 24, 2023
Pharmaceuticals
MEI Pharma, Inc. and Infinity Pharmaceuticals, Inc. entered into a definitive merger agreement for an all-stock transaction to form a combined clinical-stage oncology company. The merged organization will advance a pipeline of three clinical-stage oncology drug candidates, including eganelisib, voruciclib, and ME-344.
-
Partners Group Acquires Pharmathen from BC Partners
July 19, 2021
Pharmaceuticals
Partners Group has agreed to acquire Pharmathen, the leading European drug delivery technology and pharmaceutical manufacturing company, from BC Partners in a transaction valued at approximately EUR 1.6 billion. The deal transfers control of Pharmathen to Partners Group (acting on behalf of its clients) and is aimed at supporting the company’s continued growth — including an intensified push into the US market — building on strong R&D and manufacturing capabilities.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.